Novo Nordisk A/S: The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, is cleared to close
Bagsværd, Denmark, 14 December 2024 - As of today, all regulatory closing conditions relating to the review of Novo Holdings A/S's pending acquisition of Catalent, Inc. (Catalent), including expiry of the timing agreement in the US, have been fulfilled. Catalent is a global contract development and manufacturing organisation headquartered in New Jersey (US). The parties are now free to close the transaction, as well as Novo Nordisk's subsequent acquisition of three Catalent manufacturing sites from Novo Holdings A/S.
The agreement to acquire the three manufacturing sites was announced on 5 February 2024. For further information, please see the company announcement here.
Novo Nordisk now expects the acquisition to be completed in the coming days.
Upon completion, the acquisition is expected to impact the financial outlook as issued on 6 November 2024, with a low single-digit negative impact on operating profit growth and to negatively impact free cash flow with the 11.7 billion USD acquisition price. The ongoing share buyback programme of 20 billion DKK is not impacted.
For 2025, the acquisition is expected to have a mid single-digit negative impact on operating profit growth. The acquisition will be mainly debt-financed, with interest payments negatively impacting net financial items. Novo Nordisk's capital allocation priorities focus on internal growth investments, including supply chain expansions, dividends as well as external growth opportunities, including acquiring the three manufacturing sites. Consequently, Novo Nordisk is not expecting to initiate a share buyback programme in 2025.
Læs mere:
https://ml-eu.globenewswire.com/Resource/Download/650445ff-d6b4-414b-a72d-11c1de203c1c
Bagsværd, Denmark, 14 December 2024 - As of today, all regulatory closing conditions relating to the review of Novo Holdings A/S's pending acquisition of Catalent, Inc. (Catalent), including expiry of the timing agreement in the US, have been fulfilled. Catalent is a global contract development and manufacturing organisation headquartered in New Jersey (US). The parties are now free to close the transaction, as well as Novo Nordisk's subsequent acquisition of three Catalent manufacturing sites from Novo Holdings A/S.
The agreement to acquire the three manufacturing sites was announced on 5 February 2024. For further information, please see the company announcement here.
Novo Nordisk now expects the acquisition to be completed in the coming days.
Upon completion, the acquisition is expected to impact the financial outlook as issued on 6 November 2024, with a low single-digit negative impact on operating profit growth and to negatively impact free cash flow with the 11.7 billion USD acquisition price. The ongoing share buyback programme of 20 billion DKK is not impacted.
For 2025, the acquisition is expected to have a mid single-digit negative impact on operating profit growth. The acquisition will be mainly debt-financed, with interest payments negatively impacting net financial items. Novo Nordisk's capital allocation priorities focus on internal growth investments, including supply chain expansions, dividends as well as external growth opportunities, including acquiring the three manufacturing sites. Consequently, Novo Nordisk is not expecting to initiate a share buyback programme in 2025.
Læs mere:
https://ml-eu.globenewswire.com/Resource/Download/650445ff-d6b4-414b-a72d-11c1de203c1c
Var det ikke tæt på 100% forventet? Nogen gæt på, hvad det betyder for kursen mandag? 3% op som et lettelsessuk?
15/12 2024 08:03 ProInvestorNEWS 2
123457 Der er et bud her fra Bank of America:
https://proinvestor.com/boards/123446/
https://proinvestor.com/boards/123446/
15/12 2024 08:53 vestasfan 0123458 Hvis der ikke kommer nyt vedr. Cagrisema, så vil kursstigningen være behersket. Hvorfor købe mandag, hvis data er dårlige onsdag?
eller køb mandag, hvis du tror der kommer gode data onsdag.
18/12 2024 15:08 ProInvestorNEWS 0123500 The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, is completed
https://ml-eu.globenewswire.com/Resource/Download/b8568752-f00c-4fc1-bd3c-e34666e7215d
https://ml-eu.globenewswire.com/Resource/Download/b8568752-f00c-4fc1-bd3c-e34666e7215d
